about
Performance of a multiplex assay compared to enzyme and precipitation methods for anti-ENA testing in systemic lupus and systemic sclerosis.Anti-dsDNA, anti-Sm antibodies, and the lupus anticoagulant: significant factors associated with lupus nephritisMycophenolate mofetil and systemic lupus erythematosus: an overview.Skin manifestations of systemic lupus erythematosus refractory to multiple treatment modalities: poor results with mycophenolate mofetil.The role of immune complexes in atherogenesis.The role of cytokines as biomarkers in systemic lupus erythematosus and lupus nephritis.Systemic lupus erythematosus and infections: clinical importance of conventional and upcoming biomarkers.Management of infection in systemic lupus erythematosus.Introduction to drug allergy, and whom to refer for specialist assessment?Update on systemic vasculitides.Mannose-binding lectin deficiency and predisposition to recurrent infection in adults.Use of intravenous immunoglobulin in patients with active vasculitis associated with concomitant infection.The NIH pulse cyclophosphamide regime: the end of an era?Treatment with intravenous immunoglobulins in systemic lupus erythematosus: a series of 52 patients from a single centre.Mycophenolate mofetil in systemic lupus erythematosus: efficacy and tolerability in 86 patients.Observational safety study of specific outcomes after trivalent cell culture seasonal influenza vaccination (Optaflu® ) among adults in THIN database of electronic UK primary healthcare records.IgE deficiency may indicate underlying hypogammaglobulinaemia?PR3 antibodies: not always an immunological emergency.C-reactive protein, insulin resistance, central obesity, and coronary heart disease risk in Indian Asians from the United Kingdom compared with European whites.British Society for Immunology/United Kingdom Primary Immunodeficiency Network consensus statement on managing non‐infectious complications of Common Variable Immunodeficiency DisordersHypertension as the presenting feature of the antiphospholipid syndromeThe association of pure red cell aplasia with the antiphospholipid syndromeAutoantibodies as markers for detecting concurrent disease activity in systemic lupus erythematosusPractical management of lupus nephritis in pregnancy and the puerperiumClinical importance of autoantibodies in lupus nephritisCow's milk allergy in children. Challenge is not crucialDoxepin may be a useful pharmacotherapeutic agent in chronic urticariaThe relationship between pro-resorptive inflammatory cytokines and the effect of high dose vitamin D supplementation on their circulating concentrationsPhenindione interferes with measurement of creatinineReflex Testing of Immunoglobulins in Patients with Total Serum IgE < 2 kU/LIncreased awareness of hypogammaglobulinemia after B-cell targeting therapiesPractical Aspects of Introduction of Multiplex Bead Technology into the Routine Diagnostic Immunology LaboratoryUnusual accumulation of a wide array of antimicrobial resistance mechanisms in a patient with cytomegalovirus-associated hemophagocytic lymphohistiocytosis: a case reportRecommendations for the management of secondary hypogammaglobulinaemia due to B cell targeted therapies in autoimmune rheumatic diseasesRe: 'ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies' by Mikulska et alSoluble TNF-R1, VEGF and other cytokines as markers of disease activity in systemic lupus erythematosus and lupus nephritisImmunoglobulin replacement for secondary immunodeficiency after B-cell targeted therapies in autoimmune rheumatic disease: Systematic literature reviewA 74-year-old female with recurrent infections receiving methotrexate for rheumatoid arthritisIatrogenic antibody deficiency from B-cell targeted therapies in autoimmune rheumatic diseasesA comprehensive characterization of chronic norovirus infection in immunodeficient hosts
P50
Q33780194-16F95C7A-99A4-4804-BA6D-F1C53175CCFEQ35552732-A85A7710-643F-41DF-9D9F-88D4DE13B765Q36085845-830B2E40-CDE4-4B24-ABA2-2297D4EA0F29Q36170981-C8DFE222-E8E7-4E87-AA25-7524018F81A5Q37731718-099B5DF9-E2FF-41C4-AD39-5BC7ECAF78E5Q37849465-6FC1547B-E53B-4249-B376-5205674B6CACQ38002293-235A8A62-6D52-4336-9D6A-158706BEE8FBQ38163143-D85C4D52-FC76-4835-A3DF-7C4DA8D43244Q39032290-7CAF20A1-DDB4-4022-8F60-C4D612428E71Q39220393-A9D9478D-B2A9-4992-8240-31FBDA2B7CA6Q40808259-CEB036DD-E973-4E2C-9846-65E201F2B7AEQ41582670-0DA6FD63-81B8-42D0-8DA9-679AD28EC3D4Q44761101-DAD7CF57-9D8F-4404-9859-6A74FECFF44FQ45086512-C009718F-AECF-45C4-8041-4D835B08CD5AQ46532083-419A0109-E486-4C5D-8E18-D8A9D5527C22Q48274084-FCCEA667-8462-4B13-8826-17C4DC1D7A84Q51712817-A952231F-3558-4E3D-8F63-AAE9FFBE4EE0Q53167917-71A78EEC-2C77-4B5F-B36D-66C7E6E5391CQ54002315-ABC39330-1F07-473E-9F62-1BB7BF3DA24BQ61836808-739B024A-0E52-4926-97B8-7BD60707E95BQ74225484-2932023F-CDFC-4717-B427-AF31AAE12795Q77479829-A7B9EE75-B0E9-4464-B1C4-0D78896674F0Q82459462-210DE230-C991-4E10-AFEB-B4CC8F15EAADQ82653441-4EBBD1AF-7AC0-41FE-A684-8B50281A5A11Q84238698-CF49ECC2-B2B5-4A72-99FB-80D57B5E8782Q84525423-ACFE0C43-D7C2-4CC4-97C6-24BE78AD3141Q85289833-89997918-85DB-4622-915B-5720CF321672Q85640544-758960C1-F0F7-42B5-9570-6DEAC57ACE1CQ85653751-AE9C5866-947D-4088-BF00-9754FCD89CFCQ89358676-AAA81A77-2D48-4971-909F-7BC32190B301Q90061477-27A7AE27-8DAE-40AF-8126-BECAABDF70B3Q90157982-599CBDEA-41CF-41A9-8E61-1EDE9A76FAE4Q90464146-AE1B6474-B16C-40B5-BE89-FB9209F09D25Q90780194-AE1C0ECA-5068-4442-85FF-F4A5614980E9Q90807022-9937BD2A-B86E-4DDD-B6DE-95F402599582Q91697715-B883E8EC-3900-4B8B-93CC-ED97ABB29A31Q92193528-5EA44C9E-F4A7-4F6C-8142-546BD9176284Q92414908-5C83665D-C71F-440E-BED2-46485B05D81AQ92627999-0649ABC2-984D-401F-8982-9A3AC089BE26Q92639655-97EE8AC3-EDE1-4278-B7D5-3F0CD597E4F6
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Y Karim
@ast
Y Karim
@en
Y Karim
@es
Y Karim
@nl
Y Karim
@sl
type
label
Y Karim
@ast
Y Karim
@en
Y Karim
@es
Y Karim
@nl
Y Karim
@sl
prefLabel
Y Karim
@ast
Y Karim
@en
Y Karim
@es
Y Karim
@nl
Y Karim
@sl
P106
P1153
6603468186
P31
P496
0000-0003-0912-1629